Abolfazl Barzegari
Associate Professor
Research Interests
Explore related searches
Contact this professor
Get a free first email built on one of their papers, ready for you to edit and send yourself.
About
Abolfazl Barzegari is an Associate Professor at the Laboratory for Vascular Translational Science in France. His research interests encompass a range of areas, including the role of microRNAs in coronary artery disease, the effects of dietary supplements on health outcomes in various diseases, and innovative drug delivery systems for cancer therapy. He has contributed to numerous studies focused on the mechanisms of action of therapeutic compounds and bioregulatory factors in cardiovascular and oncological contexts.
Articles (15)
Year:
2025
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2023
Year:
2023
Introduction: Mesoporous silica nanoparticles (MSNPs) are considered innovative multifunctional structures for targeted drug delivery owing to their outstanding physicochemical characteristics. Methods: MSNPs were fabricated using the sol-gel method, and polyethylene glycol-600 (PEG600) was used for MSNPs modification. Subsequently, sunitinib (SUN) was loaded into the MSNPs, MSNP-PEG and MSNP-PEG/SUN were grafted with mucin 16 (MUC16) aptamers. The nanosystems (NSs) were characterized using FT-IR, TEM, SEM, DLS, XRD, BJH, and BET. Furthermore, the biological impacts of MSNPs were evaluated on the ovarian cancer cells by MTT assay and flow cytometry analysis. Results: The results revealed that the MSNPs have a spherical shape with an average dimension, pore size, and surface area of 56.10 nm, 2.488 nm, and 148.08 m2g-1, respectively. The cell viability results showed higher toxicity of targeted MSNPs in MUC16 overexpressing OVCAR-3 cells as compared to the SK-OV-3 cells; that was further confirmed by the cellular uptake results. The cell cycle analysis exhibited that the induction of sub-G1 phase arrest mostly occurred in MSNP-PEG/SUN-MUC16 treated OVCAR-3 cells and MSNP-PEG/SUN treated SK-OV-3 cells. DAPI staining showed apoptosis induction upon exposure to targeted MSNP in MUC16 positive OVCAR-3 cells. Conclusion: According to our results, the engineered NSs could be considered an effective multifunctional targeted drug delivery platform for the mucin 16 overexpressing cells.
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Year:
2022
Year:
2020
Year:
2020
Year:
2020
Collaborators (6)
Violeta Rodriguez-Ruiz
Assistant Professor
Lab. ERRMECe, CY Cergy Paris Université, Maison Internationale de la Recherche
Jaleh Barar
-
Anne Meddahi-Pellé
Professeur des Universités
Sorbonne Université
Graciela Pavon‐Djavid
Sorbonne Université
Yadollah Omidi
Professor of Pharmaceutical Sciences
Nova Southeastern University
Mohammmad Asghari Jafarabadi
Professor
MONASH UNIVERSITY
Make your next move.
Prepare your application
Review drafts before you send them.